Track Record of Identifying Rare Wealth CreatorsTrack Record of Identifying Rare Wealth Creators
Manish Goel - SEBI Registered Investment Adviser

About Manish Goel

SEBI Registered Investment Adviser • Chartered Accountant

423 Articles Published

Manish Goel is a Chartered Accountant and the Founder of Multibagger Securities Research & Advisory Pvt. Ltd. (SEBI Registered Investment Adviser, INA100007736). A full-time value investor since 2010, he has helped thousands of investors build long-term wealth through quality stock picking and disciplined fundamental analysis.

May 23, 2026
Hero page with title 'The IKEA Effect' and four colored blocks: top-left Lucky (gray), top-right DISCIPLINED INVESTOR (green), bottom-left Confused (light gray), bottom-right BIAS-TRAPPED (orange).

The IKEA Effect: Norton, Mochon & Ariely’s 2012 Discovery That Labour Leads to Love

In 2011, three behavioural economists at Harvard Business School and Duke University — Michael I. Norton, Daniel Mochon and Dan Ariely — conducted a series of […]
May 23, 2026
Infographic: Employee Cost-to-Revenue Ratio by fiscal year, rising from FY20 (14) to FY25 (22); FY25 bar is green.

Employee Cost-to-Revenue Ratio: How a Single P&L Line Reveals Operating Leverage, Wage Discipline & Hidden Margin Risk

The Employee Benefit Expense line is the cleanest fixed-cost intensity metric on any Indian P&L. Here is how to read it, benchmark it, and use it — illustrated with Titan Biotech FY25's audited markers.
May 23, 2026
Headline: Marathon’s Capital Cycle Theory with a green accent bar and subtitle against a dark blue gradient background, centered donut chart labeled FY25 Reinvested at the bottom.

Marathon’s Capital Cycle Theory: The Supply-Side Framework That Spots India’s Next Multibagger Industries Before the Headlines Do

Marathon Asset Management's Capital Cycle Theory tells Indian value investors to count plants, not consumers — the supply-side framework that predicts industry returns better than any demand forecast.
May 22, 2026
Horizontal bar chart of yearly values from FY20 to FY25: FY20 28, FY21 26, FY22 22, FY23 18, FY24 14, FY25 11; final bar is green.

Choice Overload & The Paradox of Choice: Iyengar & Lepper’s 2000 Jam Study and Sethi-Iyengar-Huberman-Jiang 2004 401(k) Evidence

Iyengar & Lepper’s 2000 jam study and Sethi-Iyengar’s 2004 401(k) evidence show that wider option sets paralyse decision-makers. With ~1,500 MF schemes and 5,000+ listed stocks, Indian retail investors face an extreme choice-overload landscape. A four-step counter-measure checklist, and an educational case study on how Titan Biotech (BSE: 524717) FY25’s focused specialty-biotech portfolio reads as anti-choice-overload corporate behaviour.
+91-7380122211